Cornerstone actively partners with the leading innovative researchers, universities and companies in order to further the development of drug candidates from bench to bedside. Working hand in hand with our World-Leading Scientific and Medical Advisory Boards, we apply a complex and rigorous evaluation process in order to select the most promising projects for development. Once a project is accepted, we design a comprehensive drug development plan and assume full responsibility for its advancement and success. Throughout the development process, our team actively involves the inventors, companies and universities as partners in the drug development program.


Once our candidate compounds have achieved advanced stages of drug development, we may seek out-licensing and other strategic alliances for further development, manufacturing, and launching the drug as a commercial pharmaceutical product in selective geographies. CPI-613® (devimistat), our first in class clinical lead compound, is a prime candidate for out-licensing outside of the U.S. and co-development. CPI-613® (devimistat) has already generated impressive results in clinical trials in combination with other therapies.

Learn more about CPI-613® (devimistat)

In addition to CPI-613® (devimistat), Cornerstone has a robustly innovative pipeline of drugs at various stages of clinical and pre-clinical development.

If you are interested in exploring a partnership with Cornerstone please contact